NO960309L - Agonists and antagonists of human interleukin-10 - Google Patents

Agonists and antagonists of human interleukin-10

Info

Publication number
NO960309L
NO960309L NO960309A NO960309A NO960309L NO 960309 L NO960309 L NO 960309L NO 960309 A NO960309 A NO 960309A NO 960309 A NO960309 A NO 960309A NO 960309 L NO960309 L NO 960309L
Authority
NO
Norway
Prior art keywords
agonists
antagonists
human
human interleukin
preparations
Prior art date
Application number
NO960309A
Other languages
Norwegian (no)
Other versions
NO960309D0 (en
Inventor
Chuan-Chu Chou
Xia-Yan Cai
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO960309D0 publication Critical patent/NO960309D0/en
Publication of NO960309L publication Critical patent/NO960309L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Agonister og antagonister for humant IL-10 er tilveiebrakt ved hjelp av denne oppfinnelsen som er basert på modifikasjon av endene til fullstendig, | humant IL-10. Det er også tilveiebrakt j preparater og fremgangsmåter for til- i førsel eller inhibering av den biolog- iske aktivitet av humant IL-10. Slike preparater kan være anvendbare ved be- handlingen av sykdommer kjennetegnet ved upassende Th-responser. Nuklein- syrer som koder for agonistene og antagonistene, rekombinante vektorer og : transformerte vertsceller som omfatter j slike nukleinsyrer, og fremgangsmåter i for fremstilling av agonistene og 1 antagonistene under anvendelse av de transformerte vertsceller, er også til- veiebrakt.Agonists and antagonists for human IL-10 are provided by this invention based on modification of the ends to complete, | human IL-10. Preparations and methods are also provided for the delivery or inhibition of the biological activity of human IL-10. Such preparations may be useful in the treatment of diseases characterized by inappropriate Th responses. Nucleic acids encoding the agonists and antagonists, recombinant vectors and: transformed host cells comprising such nucleic acids, and methods for preparing the agonists and 1 antagonists using the transformed host cells, are also provided.

NO960309A 1993-07-26 1996-01-25 Agonists and antagonists of human interleukin-10 NO960309L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9894393A 1993-07-26 1993-07-26
PCT/US1994/008052 WO1995003411A1 (en) 1993-07-26 1994-07-22 Agonists and antagonists of human interleukin-10

Publications (2)

Publication Number Publication Date
NO960309D0 NO960309D0 (en) 1996-01-25
NO960309L true NO960309L (en) 1996-01-25

Family

ID=22271670

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960309A NO960309L (en) 1993-07-26 1996-01-25 Agonists and antagonists of human interleukin-10

Country Status (17)

Country Link
EP (1) EP0711346A1 (en)
JP (1) JPH08507930A (en)
KR (1) KR960704041A (en)
CN (1) CN1127529A (en)
AU (1) AU681178B2 (en)
CA (1) CA2168110A1 (en)
CZ (1) CZ23396A3 (en)
FI (1) FI960353A0 (en)
HU (1) HUT73463A (en)
IL (1) IL110413A0 (en)
NO (1) NO960309L (en)
NZ (1) NZ269663A (en)
PL (1) PL312718A1 (en)
SG (1) SG43798A1 (en)
SK (2) SK8396A3 (en)
WO (1) WO1995003411A1 (en)
ZA (1) ZA945434B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ1497A3 (en) * 1994-07-05 1997-05-14 Steeno Res Group As Polypeptide, its use and pharmaceutical composition based thereon, a nucleotide sequence and antibody
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
AUPN481295A0 (en) * 1995-08-16 1995-09-07 Medvet Science Pty. Ltd. Agonists of haemopoietic growth factors
WO1997026278A1 (en) 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
DE19851675A1 (en) * 1998-11-10 2000-05-11 Bayer Ag Human interleukin-10 mutant proteins
WO2001074388A1 (en) 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
EP1324779B1 (en) 2000-09-29 2011-07-20 Schering Corporation Pegylated interleukin-10
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
EP1712241A1 (en) 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
LT2816118T (en) 2005-05-31 2018-12-10 The Regents Of The University Of Colorado, A Body Corporate Methods for delivering genes
BRPI0719446A2 (en) 2006-09-28 2013-12-10 Schering Corp Use of pegylated IL-10 to treat cancer
CN102227447A (en) 2008-10-02 2011-10-26 新兴产品开发西雅图有限公司 Cd86 antagonist multi-target binding proteins
ES2957546T3 (en) 2008-12-17 2024-01-22 Merck Sharp & Dohme Production of mono- and di-PEG-IL10; and uses
DK2776460T3 (en) 2011-11-08 2018-08-06 Umc Utrecht Holding Bv Fusion protein comprising interleukin 4 and interleukin 10
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc Methods of using interleukin-10 for treating diseases and disorders
WO2014176373A2 (en) * 2013-04-24 2014-10-30 Armo Biosciences, Inc. Interleukin-10 compositions and uses thereof
EP3434277A1 (en) 2013-06-17 2019-01-30 Armo Biosciences, Inc. Method for assessing protein identity and stability
AU2014311432A1 (en) 2013-08-30 2016-03-03 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20160079114A (en) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 Methods of using interleukin-10 for treating diseases and disorders
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
US10350270B2 (en) 2014-10-14 2019-07-16 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
MX2017004983A (en) 2014-10-22 2017-11-13 Armo Biosciences Inc Methods of using interleukin-10 for treating diseases and disorders.
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20180020141A (en) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 PEGylated interleukin-10 for cancer treatment
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
CA3137058A1 (en) 2019-04-19 2020-10-22 Synerkine Pharma B.V. A fusion protein comprising il13

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01113229A (en) * 1987-10-27 1989-05-01 Inahata Kenkyusho:Kk Porous material of honeycomb structure
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
PT600970E (en) * 1991-08-06 2000-05-31 Schering Corp USE OF INTERLEUCIN-10 ANALOGUES OR ANTAGONISTS TO TREAT ENDOTOXIN-INDUCED TOXICITY OR SUPERANTIGENS

Also Published As

Publication number Publication date
WO1995003411A1 (en) 1995-02-02
FI960353A (en) 1996-01-26
HU9503983D0 (en) 1996-03-28
NO960309D0 (en) 1996-01-25
SG43798A1 (en) 1997-11-14
EP0711346A1 (en) 1996-05-15
CN1127529A (en) 1996-07-24
AU7399694A (en) 1995-02-20
PL312718A1 (en) 1996-05-13
AU681178B2 (en) 1997-08-21
SK150596A3 (en) 1997-04-09
CA2168110A1 (en) 1995-02-02
ZA945434B (en) 1995-01-23
HUT73463A (en) 1996-08-28
FI960353A0 (en) 1996-01-26
IL110413A0 (en) 1994-10-21
JPH08507930A (en) 1996-08-27
CZ23396A3 (en) 1996-05-15
NZ269663A (en) 1997-09-22
KR960704041A (en) 1996-08-31
SK8396A3 (en) 1997-03-05

Similar Documents

Publication Publication Date Title
NO960309L (en) Agonists and antagonists of human interleukin-10
RU95115239A (en) Erythropoietin analog
NO952974L (en) G-CSF analog preparations and methods
DE68929043T2 (en) DNA ENCODING ANDROGEN RECEPTOR PROTEIN
DK43890A (en) NUCLEIC ACID, VECTORS AND CELLS CONTAINING THE PRODUCED PRODUCTS AND THEIR USE THEREOF
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
NO177678C (en) Method for Preparing a Therapeutically Active, Recombinant Protein having ASP Activity, Expression System, and DNA Encoding the Protein
CA2080462A1 (en) Therapeutic uses of actin-binding compounds
MY102472A (en) Preparation of funtional human urokinase proteins.
DK1005540T3 (en) IKK-beta proteins, nucleic acids and methods
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
NO177716C (en) Method for Preparation of Therapeutically Active Polypeptides, DNA Sequence, Expression Vector and Antibody
DK1025236T3 (en) Human checkpoint kinase, HCDS1, preparations and methods
ATE246247T1 (en) VARIANTS OF THE HUMAN RECOMBINANT INTERFERON GAMMA (RHU-IFN-GAMMA) WITH INCREASED THERMAL STABILITY
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
EA200001124A1 (en) METHOD OF GENE THERAPY
FI893681A0 (en) N-2,3-BUTADIENYLTRY-TETRA AMINO ALKANDANDERS.
NO890174L (en) RECOMBINANT INTERLEUKIN-1ALFA POLYPEPTIDES.
EP0816504A3 (en) Platelet activating factor acetylhdrolase, and gene thereof
PT90739A (en) METHOD FOR PREPARING A PROTEIN PROVIDED WITH TROMBIN INABICATION ACTIVITY
DK0805204T3 (en) Biticle - specifically receptor protein and its use
DE68914397T2 (en) Human lymphotoxin.
KR900700604A (en) Cucumber mosaic virus coat protein gene
AU1318797A (en) Peptides and uses thereof for therapy of celiac diseases
ATE300554T1 (en) CONNECTIVE TISSUE GROWTH FACTOR 3.